Literature DB >> 2146503

Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis.

H Heijboer1, D P Brandjes, H R Büller, A Sturk, J W ten Cate.   

Abstract

BACKGROUND: Isolated deficiencies of antithrombin III, protein C, protein S, and plasminogen have been implicated as a cause of deep-vein thrombosis. It is assumed that patients with recurrent, familial, or juvenile thrombosis are very likely to have such a deficiency.
METHODS: We studied the prevalence of isolated deficiencies of these proteins in 277 consecutive outpatients with venographically proved acute deep-vein thrombosis, as compared with 138 age-matched and sex-matched controls without deep-vein thrombosis, and calculated the positive predictive value of a history of recurrent, familial, or juvenile venous thromboembolism for the presence of such a deficiency.
RESULTS: The overall prevalence of deficiencies of any of these proteins in the patients with venous thrombosis was 8.3 percent (23 of 277 patients) (95 percent confidence interval, 5.4 to 12.4), as compared with 2.2 percent in the controls (3 of 138 subjects) (95 percent confidence interval, 0.5 to 6.1; P less than 0.05 for the comparison between groups). The positive predictive values for the presence of an isolated protein deficiency in patients with recurrent, familial, or juvenile deep-vein thrombosis, defined as the proportion of patients with the clinical finding who had a deficiency of one or more of the proteins, were 9, 16, and 12 percent, respectively.
CONCLUSIONS: The cause of acute venous thrombosis in most outpatients (91.7 percent) cannot be explained by abnormalities of coagulation-inhibiting and fibrinolytic proteins. The information obtained from the medical history concerning recurrent or familial venous thrombosis or the onset of the disease at a young age is not useful for the identification of patients with protein deficiencies.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2146503     DOI: 10.1056/NEJM199011293232202

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  25 in total

Review 1.  Diagnosis and management of inherited and acquired thrombophilias.

Authors:  F A Spencer; R C Becker
Journal:  J Thromb Thrombolysis       Date:  1999-04       Impact factor: 2.300

Review 2.  Inherited thrombophilia: memorandum from a joint WHO/International Society on Thrombosis and Haemostasis meeting.

Authors: 
Journal:  Bull World Health Organ       Date:  1997       Impact factor: 9.408

Review 3.  Genetics and pulmonary medicine. 4. Pulmonary embolism.

Authors:  M Laffan
Journal:  Thorax       Date:  1998-08       Impact factor: 9.139

4.  Activated protein C and retinal vein occlusion.

Authors:  B J Hunt
Journal:  Br J Ophthalmol       Date:  1996-03       Impact factor: 4.638

Review 5.  Inherited defects of the protein C anticoagulant system in childhood thrombo-embolism.

Authors:  U Nowak-Göttl; K Auberger; U Göbel; W Kreuz; R Schneppenheim; H Vielhaber; W Zenz; B Zieger
Journal:  Eur J Pediatr       Date:  1996-11       Impact factor: 3.183

Review 6.  Endothelium: the main actor in the remodelling of the retinal microvasculature in diabetes.

Authors:  M Porta
Journal:  Diabetologia       Date:  1996-06       Impact factor: 10.122

7.  Genetic thrombophilia in patients with VTE in eastern Mediterranean located tertiary care center; is it time to change the algorithm for thrombophilia work up decision making?

Authors:  H Isma'eel; R El Accaoui; W Shamseddeen; A Taher; S Alam; R Mahfouz; M S Arnaout
Journal:  J Thromb Thrombolysis       Date:  2006-06       Impact factor: 2.300

Review 8.  Physiological anticoagulation. Resistance to activated protein C and venous thromboembolism.

Authors:  B Dahlbäck
Journal:  J Clin Invest       Date:  1994-09       Impact factor: 14.808

9.  Congenital protein C deficiency and superior sagittal sinus thrombosis causing isolated intracranial hypertension.

Authors:  C Confavreux; P Brunet; P Petiot; M Berruyer; M Trillet; G Aimard
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-05       Impact factor: 10.154

10.  The effects of infliximab therapy on the serum proteome of rheumatoid arthritis patients.

Authors:  Ravi C Dwivedi; Navjot Dhindsa; Oleg V Krokhin; John Cortens; John A Wilkins; Hani S El-Gabalawy
Journal:  Arthritis Res Ther       Date:  2009-03-06       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.